Study of MPDL3280A (ANTI PD-L1 ANTIBODY) in Patients with PD-L1-selected, High-risk Muscle-invasive Bladder Cancer after Surgery

Update Il y a 4 ans
Reference: EUCTR2014-005603-25

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of adjuvant MPDL3280A treatment in patients with programmed death ligand 1 (PD L1) selected muscle invasive bladder cancer (MIBC), as measured by disease-free survival (DFS)


Inclusion criteria

  • Muscle-invasive bladder cancer